These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 16931012)

  • 21. Targeting c-Src kinase enhances tamoxifen's inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins.
    Planas-Silva MD; Hamilton KN
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):535-43. PubMed ID: 17186241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of piperidine-aryl urea-based stearoyl-CoA desaturase 1 inhibitors.
    Xin Z; Zhao H; Serby MD; Liu B; Liu M; Szczepankiewicz BG; Nelson LT; Smith HT; Suhar TS; Janis RS; Cao N; Camp HS; Collins CA; Sham HL; Surowy TK; Liu G
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4298-302. PubMed ID: 18632269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors.
    Cai ZW; Wei D; Schroeder GM; Cornelius LA; Kim K; Chen XT; Schmidt RJ; Williams DK; Tokarski JS; An Y; Sack JS; Manne V; Kamath A; Zhang Y; Marathe P; Hunt JT; Lombardo LJ; Fargnoli J; Borzilleri RM
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3224-9. PubMed ID: 18479916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors.
    Cai ZW; Wei D; Borzilleri RM; Qian L; Kamath A; Mortillo S; Wautlet B; Henley BJ; Jeyaseelan R; Tokarski J; Hunt JT; Bhide RS; Fargnoli J; Lombardo LJ
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1354-8. PubMed ID: 18221875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities.
    Nie Z; Perretta C; Erickson P; Margosiak S; Lu J; Averill A; Almassy R; Chu S
    Bioorg Med Chem Lett; 2008 Jan; 18(2):619-23. PubMed ID: 18055206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis, and biological evaluation of potent c-Met inhibitors.
    D'Angelo ND; Bellon SF; Booker SK; Cheng Y; Coxon A; Dominguez C; Fellows I; Hoffman D; Hungate R; Kaplan-Lefko P; Lee MR; Li C; Liu L; Rainbeau E; Reider PJ; Rex K; Siegmund A; Sun Y; Tasker AS; Xi N; Xu S; Yang Y; Zhang Y; Burgess TL; Dussault I; Kim TS
    J Med Chem; 2008 Sep; 51(18):5766-79. PubMed ID: 18763753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays.
    Noronha G; Barrett K; Boccia A; Brodhag T; Cao J; Chow CP; Dneprovskaia E; Doukas J; Fine R; Gong X; Gritzen C; Gu H; Hanna E; Hood JD; Hu S; Kang X; Key J; Klebansky B; Kousba A; Li G; Lohse D; Mak CC; McPherson A; Palanki MS; Pathak VP; Renick J; Shi F; Soll R; Splittgerber U; Stoughton S; Tang S; Yee S; Zeng B; Zhao N; Zhu H
    Bioorg Med Chem Lett; 2007 Feb; 17(3):602-8. PubMed ID: 17113292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents.
    Radi M; Crespan E; Botta G; Falchi F; Maga G; Manetti F; Corradi V; Mancini M; Santucci MA; Schenone S; Botta M
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1207-11. PubMed ID: 18078752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitors.
    Hodous BL; Geuns-Meyer SD; Hughes PE; Albrecht BK; Bellon S; Caenepeel S; Cee VJ; Chaffee SC; Emery M; Fretland J; Gallant P; Gu Y; Johnson RE; Kim JL; Long AM; Morrison M; Olivieri PR; Patel VF; Polverino A; Rose P; Wang L; Zhao H
    Bioorg Med Chem Lett; 2007 May; 17(10):2886-9. PubMed ID: 17350837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of human estrogen receptor alpha F promoter by a protein kinase C/c-Src-dependent mechanism in osteoblast-like cells.
    Longo M; Peruzzi B; Fortunati D; De Luca V; Denger S; Caselli G; Migliaccio S; Teti A
    J Mol Endocrinol; 2006 Dec; 37(3):489-502. PubMed ID: 17170089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-Thy-1 antibody-induced neurite outgrowth in cultured dorsal root ganglionic neurons is mediated by the c-Src-MEK signaling pathway.
    Yang SH; Chen YJ; Tung PY; Lai WL; Chen Y; Jeng CJ; Wang SM
    J Cell Biochem; 2008 Jan; 103(1):67-77. PubMed ID: 17486586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The development of 2-benzimidazole substituted pyrimidine based inhibitors of lymphocyte specific kinase (Lck).
    Sabat M; VanRens JC; Laufersweiler MJ; Brugel TA; Maier J; Golebiowski A; De B; Easwaran V; Hsieh LC; Walter RL; Mekel MJ; Evdokimov A; Janusz MJ
    Bioorg Med Chem Lett; 2006 Dec; 16(23):5973-7. PubMed ID: 16997556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gold nanoparticle-based electrochemical detection of protein phosphorylation.
    Kerman K; Chikae M; Yamamura S; Tamiya E
    Anal Chim Acta; 2007 Apr; 588(1):26-33. PubMed ID: 17386790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Achiral, selective CCK2 receptor antagonists based on a 1,3,5-benzotriazepine-2,4-dione template.
    Spencer J; Gaffen J; Griffin E; Harper EA; Linney ID; McDonald IM; Roberts SP; Shaxted ME; Adatia T; Bashall A
    Bioorg Med Chem; 2008 Mar; 16(6):2974-83. PubMed ID: 18289857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of novel 2,3-diarylfuro[2,3-b]pyridin-4-amines as potent and selective inhibitors of Lck: synthesis, SAR, and pharmacokinetic properties.
    Martin MW; Newcomb J; Nunes JJ; Bemis JE; McGowan DC; White RD; Buchanan JL; DiMauro EF; Boucher C; Faust T; Hsieh F; Huang X; Lee JH; Schneider S; Turci SM; Zhu X
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2299-304. PubMed ID: 17276681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.
    Claridge S; Raeppel F; Granger MC; Bernstein N; Saavedra O; Zhan L; Llewellyn D; Wahhab A; Deziel R; Rahil J; Beaulieu N; Nguyen H; Dupont I; Barsalou A; Beaulieu C; Chute I; Gravel S; Robert MF; Lefebvre S; Dubay M; Pascal R; Gillespie J; Jin Z; Wang J; Besterman JM; MacLeod AR; Vaisburg A
    Bioorg Med Chem Lett; 2008 May; 18(9):2793-8. PubMed ID: 18434145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development.
    Wittman MD; Carboni JM; Yang Z; Lee FY; Antman M; Attar R; Balimane P; Chang C; Chen C; Discenza L; Frennesson D; Gottardis MM; Greer A; Hurlburt W; Johnson W; Langley DR; Li A; Li J; Liu P; Mastalerz H; Mathur A; Menard K; Patel K; Sack J; Sang X; Saulnier M; Smith D; Stefanski K; Trainor G; Velaparthi U; Zhang G; Zimmermann K; Vyas DM
    J Med Chem; 2009 Dec; 52(23):7360-3. PubMed ID: 19778024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 4-Anilino-7-pyridyl-3-quinolinecarbonitriles as Src kinase inhibitors.
    Zhang N; Wu B; Boschelli DH; Golas JM; Boschelli F
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5071-4. PubMed ID: 19632113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of a novel series of quinoxalines as inhibitors of c-Met kinase.
    Porter J; Lumb S; Lecomte F; Reuberson J; Foley A; Calmiano M; le Riche K; Edwards H; Delgado J; Franklin RJ; Gascon-Simorte JM; Maloney A; Meier C; Batchelor M
    Bioorg Med Chem Lett; 2009 Jan; 19(2):397-400. PubMed ID: 19059779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolism and pharmacokinetics of a novel Src kinase inhibitor TG100435 ([7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine) and its active N-oxide metabolite TG100855 ([7-(2,6-dichloro-phenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-{4-[2-(1-oxy-pyrrolidin-1-yl)-ethoxy]-phenyl}-amine).
    Hu SX; Soll R; Yee S; Lohse DL; Kousba A; Zeng B; Yu X; McPherson A; Renick J; Cao J; Tabak A; Hood J; Doukas J; Noronha G; Martin M
    Drug Metab Dispos; 2007 Jun; 35(6):929-36. PubMed ID: 17371799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.